Kamada (KMDA) Return on Capital Employed (2018 - 2026)
Kamada (KMDA) reported Return on Capital Employed of 2207.9% for Q1 2026, up 42092.0% on a YoY basis from N/an in Q1 2025, and up 2.94% quarter-over-quarter from 2144.86% in Q4 2025.
Kamada (KMDA) Return on Capital Employed (2018 - 2026) Analysis & Trends
Kamada has reported Return on Capital Employed for 9 years, with the latest figure at 2207.9% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 42092.0% year-over-year to 2207.9%; the trailing twelve-month figure through Mar 2026 stood at 2207.9% (up 42092.0% YoY), and the FY2025 full-year result was 8.0%, up 161.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 2207.9%, up from 2144.86% in the prior quarter.
- The five-year high for Return on Capital Employed was 2207.9% in Q1 2026, with the low at 2.42% in Q2 2022.
- Historically, Return on Capital Employed has averaged 949.94% across 5 years, with a median of 104.01% in 2023.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 993 bps — and 2024, when it surged 184372 bps.
- Kamada's Return on Capital Employed stood at 1.6% in 2022, then jumped by 6187 bps to 100.81% in 2023, then soared by 1696 bps to 1810.32% in 2024, then advanced by 18 bps to 2144.86% in 2025, then increased by 3 bps to 2207.9% in 2026.
- The last three Return on Capital Employed figures came in at 2207.9% (Q1 2026), 2144.86% (Q4 2025), and 2183.04% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 8.52% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 27.58% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 21.43% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 20.04% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 7.34% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 6.92% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 14.85% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -1.92% |
| 10 | Kamada | 505.05 | -73.15 Mn | 19.12 Mn | 2,207.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,207.90% |
| Dec 31, 2025 | 2,144.86% |
| Sep 30, 2025 | 2,183.04% |
| Jun 30, 2025 | 2,175.49% |
| Mar 31, 2025 | 1,786.98% |
| Dec 31, 2024 | 1,810.32% |
| Sep 30, 2024 | 1,782.29% |
| Jun 30, 2024 | 1,845.53% |
| Mar 31, 2024 | 4.43% |
| Dec 31, 2023 | 100.81% |
| Sep 30, 2023 | 104.01% |
| Jun 30, 2023 | 1.80% |
| Mar 31, 2023 | 1.80% |
| Dec 31, 2022 | 1.60% |
| Sep 30, 2022 | 1.60% |
| Jun 30, 2022 | -2.42% |
| Mar 31, 2022 | -1.05% |
| Dec 31, 2021 | -0.33% |
| Sep 30, 2021 | 2.77% |
| Jun 30, 2021 | 7.38% |